This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Croisier, D. Articles by Chavanet, P. Search for Related Content PubMed PubMed Citation Articles by Croisier, D. Articles by Chavanet, P.

Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy

Service des Maladies Infectieuses, Microbiologie Médicale et Moléculaire, Hôpital du Bocage, 21034 Dijon Cedex, France,

Received 15 April 2003/ Returned for modification 10 December 2003/ Accepted 27 January 2004

For some pneumococci the fluoroquinolone MICs are low but the mutant prevention concentrations (MPCs) are high; this difference defines in vitro the mutant selection window (MSW). We investigated in vivo the bacterial reduction and the occurrence of resistant mutants with moxifloxacin (MFX; 400 mg once daily) or levofloxacin (LVX; 500 mg twice daily) in treatments similar to those in humans with experimental pneumonia due to pneumococci (expPP) exhibiting various MICs and MPCs. The MIC/MPC for MFX and LVX and genotypes were as follows: strain 16089, 0.125/0.125 and 0.5/0.5 (wild type); strain MS1A, 0.25/0.25 and 1/2 (efflux); strain MS2A, 0.25/4 and 1.75/28 (parC79); strain MR3B4, 0.25/4 and 2/32 (parC79); strain M16, 0.5/2 and 8/32 (parC83); strain Gyr-1207, 1.5/3 and 8/16 (gyrA); and strain MQ3A, 4/4 and 16/64 (parC and gyrA). Both drugs were efficient with wild type-expPP, but only MFX was efficient with efflux-expPP. No bacterial reduction was observed for parC-expPPs due to mutants observed in 18 to 100% of animals, depending on the strain and the drug tested. These mutants showed unbound area under the concentration-time curve and MICs of from 50 to 164 for MFX. The in vivo pharmacodynamic boundaries of the MSW were different for MFX and LVX. We conclude that, after LVX or MFX treatment, mutants occur in vivo if there is a preexisting parC mutation, since the drug concentrations fall below the MPCs of these strains. Since the MPC determination cannot be routinely determined, these phenotypes or genotypes should be detected by simple tests to guide the therapeutic options.

This article has been cited by other articles:

• de Cueto, M., Rodriguez, J. M., Soriano, M. J., Lopez-Cerero, L., Venero, J., Pascual, A. (2008). Fatal Levofloxacin Failure in Treatment of a Bacteremic Patient Infected with Streptococcus pneumoniae with a Preexisting parC Mutation. J. Clin. Microbiol. 46: 1558-1560 [Abstract] [Full Text]  
• Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
• Pletz, M. W. R., Shergill, A. P., McGee, L., Beall, B., Whitney, C. G., Klugman, K. P., for the Active Bacterial Core Surveillance Team, (2006). Prevalence of First-Step Mutants among Levofloxacin-Susceptible Invasive Isolates of Streptococcus pneumoniae in the United States.. Antimicrob. Agents Chemother. 50: 1561-1563 [Abstract] [Full Text]  
• Wetzstein, H.-G. (2005). Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance. Antimicrob. Agents Chemother. 49: 4166-4173 [Abstract] [Full Text]  
• Epstein, B. J, Gums, J. G, Drlica, K. (2004). The Changing Face of Antibiotic Prescribing: The Mutant Selection Window. The Annals of Pharmacotherapy 38: 1675-1682 [Abstract] [Full Text]  
• Croisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H., Chavanet, P. (2004). In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 54: 640-647 [Abstract] [Full Text]